22 May 2024 in European Urology
11 November 2022 in Nature Reviews Urology
11 March 2022 in European Urology Focus
Succinate dehydrogenase-deficient and fumarate hydratase-deficient renal cell carcinomas (SDHRCC and FHRCC) are rare kidney cancers driven by loss of TCA cycle enzymes. To define and compare the genomic and metabolomic hallmarks of SDHRCC and FHRCC. We analyzed SDHRCC and FHRCC tumors with either immunohistochemical evidence of loss of protein expression or genomically confirmed biallelic inactivation of SDHA/B/C/D/AF2 or FH. Somatic alterations were identified using clinical pipelines, with allele-specific copy number alterations (CNAs) identified using FACETS. Mass spectrometry–based metabolomic profiling was performed on available SDHRCC and FHRCC tumors. Tumors were analyzed for 42 patients (25 FHRCC, 17 SDHRCC). In the germline analysis, 16/17 SDHRCCs harbored a germline alteration in SDHB, whereas only 17/22 FHRCCs had pathogenic germline FH variants. SDHRCCs had a lower mutation burden (p = 0.02) and CNA burden (p = 0.0002) than FHRCCs. All SDHRCCs presented with deletion of chromosome 1p (overlapping SDHB), whereas FHRCCs demonstrated high but not ubiquitous loss of 1q (FH locus). Both SDHRCCs and FHRCCs exhibited significant idiopathic accumulation of the metabolite guanine. FHRCC tumors had elevated levels of urea cycle metabolites (argininosuccinate, citrulline, and fumarate), whereas SDHRCC tumors had elevation of numerous acylcarnitines. These characteristic metabolic changes allowed identification of a previously unrecognized SDH-deficient RCC. Despite sharing similar genetic etiology, SDHRCC and FHRCC represent distinct molecular entities with unique genetic and metabolic abnormalities. Kidney cancers driven by loss of the gene encoding either the succinate dehydrogenase or fumarate hydratase enzyme are rare. We sought to define and compare the genetic and metabolic features of these cancer entities.
4 November 2022 in European Urology
23 December 2021 in Leukemia & Lymphoma
The human B-cell marker CD19 is highly expressed in many non–Hodgkin's lymphomas and leukemias, and therefore offer an appealing immunotherapeutic target for cancers of lymphoid origin [1]. Anti-CD...
1 October 2025 in JCO Oncology Advances
PURPOSE: Black patients with metastatic prostate cancer (mPCa) are less likely to receive somatic testing than their White counterparts. Our objective was to develop a culturally tailored educational tool intended to increase somatic testing participation. METHODS: We conducted a multisite qualitative study to develop the tool, informed by the human-centered design (HCD) principles Inspiration and Ideation, and the capability-opportunity-motivation-behavior (COM-B) framework. We approached stakeholders to codesign a prototype, iteratively refined the tool through semistructured interviews with Black patients with mPCa, and identified likes , wishes , questions , and ideas until data saturation. We analyzed interviews via COM-B into barriers/facilitators of two behaviors: (1) tool engagement and (2) somatic testing participation. RESULTS: Four physicians, one genetic counselor, and two patients codesigned an electronic tool, consisting of an 8-minute video of a non-Hispanic Black physician and animations followed by a text-based decision aid. We reached data saturation after interviewing 11 patients (61% of 18 approached). Participants liked the tool's cultural tailoring, wished for more information on somatic testing benefits, and questioned content gaps. Their ideas reflected cost concerns. Ten participants expressed a desire to obtain and/or speak with their oncologist about somatic testing. We identified barriers/facilitators of tool engagement and somatic testing participation, which led to changing the text-based decision aid into a Q&A format and tailoring the content to address race, cost, and biopsy-related concerns. CONCLUSION: HCD and COM-B frameworks enabled the development of a culturally tailored educational tool for Black patients with mPCa. This educational tool was well received and might have contributed to increased interest in somatic testing participation. Further research to evaluate the feasibility, acceptability, and efficacy of the tool in clinical workflows is needed.